Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 11;186(10):2176-2192.e22.
doi: 10.1016/j.cell.2023.04.009. Epub 2023 May 2.

Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival

Affiliations
Free article

Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival

David M Hoi et al. Cell. .
Free article

Abstract

The ClpC1:ClpP1P2 protease is a core component of the proteostasis system in mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease, we characterized the mechanism of the antibiotics cyclomarin A and ecumicin. Quantitative proteomics revealed that the antibiotics cause massive proteome imbalances, including upregulation of two unannotated yet conserved stress response factors, ClpC2 and ClpC3. These proteins likely protect the Clp protease from excessive amounts of misfolded proteins or from cyclomarin A, which we show to mimic damaged proteins. To overcome the Clp security system, we developed a BacPROTAC that induces degradation of ClpC1 together with its ClpC2 caretaker. The dual Clp degrader, built from linked cyclomarin A heads, was highly efficient in killing pathogenic Mycobacterium tuberculosis, with >100-fold increased potency over the parent antibiotic. Together, our data reveal Clp scavenger proteins as important proteostasis safeguards and highlight the potential of BacPROTACs as future antibiotics.

Keywords: BacPROTAC; Clp protease; ClpC1; Mycobacterium tuberculosis; antibiotics; cyclomarin A; ecumicin; protein quality control; small-molecule degrader; targeted protein degradation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests K.F., V.M.S., K.R., H.W., and G.B. were employees of Boehringer Ingelheim at the time of this work.

Comment in

  • BacPROTAC to treat tuberculosis.
    Crunkhorn S. Crunkhorn S. Nat Rev Drug Discov. 2023 Jun;22(6):448. doi: 10.1038/d41573-023-00073-1. Nat Rev Drug Discov. 2023. PMID: 37142699 No abstract available.

Publication types

MeSH terms

LinkOut - more resources